Medical Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

Combination of naloxone-oxycodone:
1. At present (2018) available in Canada but not in the United States.
2. Combination agent orally administered which relieves constipation in the context of continued requirement for opioid pain relief.
3. Both
4. Neither
Naloxone + oxycodone:
1. Following oral administration naloxone blocks oxycodone effects in the G.I. tract while permitting centrally mediated analgesia.
2. This combination agent eliminates typical risks associated with opioids including respiratory depression and addiction.
3. Both
4. Neither
Adverse effect(s) associated with administration of naloxone + oxycodone:
1. Nausea and vomiting
2. Diarrhea
3. Constipation
4. A & B
5. B & C
6. A & C
7. A, B & C
Alvimopan (Entereg) administration:
1. This agent is a μ-type of opioid receptor blocker.
2. Administration of alvimopan induces more spontaneous bowel movements and enhances other opioid-induced constipation presentations without interfering with analgesia.
3. Both
4. Neither
Approved use(s) for alvimopan:
1. Appropriate for managing opioid-induced constipation
2. Management of postoperative bowel recovery.
3. Both
4. Neither
Prokinetic drugs are typically effective in managing postoperative ileus.
1. True
2. False
Alvimopan:
1. Orally effective
2. "Peripherally restricted" μ opioid receptor blocker
3. Both
4. Neither
Alvimopan is a prodrug, requiring activation by G.I. flora to the amide.
1. True
2. False
Alvimopan administration: prior to surgery (30 minto five hours) then subsequent to surgery without exceeding 15 total doses.
1. True
2. False
Alvimopan adverse effect(s):
1. Hypokalemia
2. Anemia
3. Dyspepsia
4. A & B
5. B & C
6. A & C
7. A, B & C

Medical Pharmacology: Gastrointestinal Pharmacology Practice Questions